Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and laser ablation, has reportedly raised over RMB 100 million (USD 13.8 million) in a new financing round. Investors include Nanjing NII Group, Huatai Zijin, Peiyang Begonia Fund, Andon Health, and bioVenture, with Starboard Value serving as the exclusive financial advisor.
Funding Use
The company plans to use the proceeds to accelerate research and development, manufacturing, regulatory filings, and commercialization efforts.
Company Profile
Founded in 2016, Horimed offers a range of products, including intravascular ultrasound (IVUS) equipment and catheters, optical coherence tomography (OCT) equipment and catheters, an IVUS/OCT integrated dual catheter system, a non-invasive fractional flow reserve (FFR) platform based on IVUS and OCT, single source dual-mode OCT-NIRS technology integrating OCT and near-infrared spectroscopy (NIRS), and intravascular laser plaque ablation technology.-Fineline Info & Tech
